Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:10 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 1,898 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Effect of Drug Clear all

Conditions: Healthy Volunteers
Interventions: TAK-935 Tablets, TAK-935 Oral Solution; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Glendale, California

Conditions: Carcinoid Syndrome
Interventions: Octreotide; Drug
Lead sponsor: Endo USA Inc., a Keenova Therapeutics Company; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 3
States / cities: Iowa City, Iowa • Boston, Massachusetts • Burlington, Massachusetts

Conditions: Sarcopenia
Interventions: Culinary Medicine, Control; Behavioral
Lead sponsor: Texas Tech University; Other
Eligibility: 65 Years and older
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Lubbock, Texas

Conditions: Hypertension
Interventions: Intervention Values Affirmation, Control Values Affirmation; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 21 Years to 100 Years
Enrollment: 960 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2021
U.S. locations: 3
States / cities: Denver, Colorado • Rockville, Maryland

Conditions: Diastolic Dysfunction, Hypertension
Interventions: Valsartan; Drug
Lead sponsor: Novartis; Industry
Eligibility: 45 Years and older
Enrollment: 317 participants
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Healthy
Interventions: Opevesostat, Prednisone, Fludrocortisone acetate, Itraconazole; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 19 Years to 55 Years · Male only
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases, Respiratory Tract Infections
Interventions: Low dose of quadrivalent VLP vaccine, Medium dose of quadrivalent VLP vaccine, High dose of quadrivalent VLP vaccine, Placebo; Biological
Lead sponsor: Medicago; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Older Adults (65 Years and Older)
Interventions: Not listed
Lead sponsor: Michigan State University; Other
Eligibility: 65 Years and older
Enrollment: 82 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: East Lansing, Michigan

Conditions: Depression
Interventions: desvenlafaxine SR, desipramine, paroxetine; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Neptune City, New Jersey

Conditions: Neuromuscular Agents, Peripheral Nervous System Agents, Physiological Effects of Drugs, Acetylcholine Release Inhibitors, Membrane Transport Modulators, Molecular Mechanisms of Pharmacological Action, Cholinergic Agents, Neurotransmitter Agents, incobotulinumtoxinA, Botulinum Toxins, Type A
Interventions: NT 201, NT 201 Placebo; Drug
Lead sponsor: Merz North America, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 27
States / cities: Scottsdale, Arizona • Encino, California • Los Angeles, California + 22 more

Conditions: Infection, Alcohol Abuse, Drugs of Abuse, Lung Injury
Interventions: Characterize alcohol and drug use; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 90 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2029
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Advanced Malignant Solid Neoplasm
Interventions: Adavosertib, Carboplatin, Everolimus, Temozolomide, Trametinib, Veliparib; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 208 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 8
States / cities: Aurora, Colorado • Atlanta, Georgia • Lexington, Kentucky + 5 more

Conditions: Mycobacterium Avium-intracellulare Infection, HIV Infections, Pneumococcal Infections
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 326 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2000
U.S. locations: 15
States / cities: San Francisco, California • Denver, Colorado • Washington D.C., District of Columbia + 11 more

Conditions: Healthy
Interventions: PA21 and Furosemide with food, No PA21; Furosemide with food, PA21 with food and Furosemide 2hrs later; Drug
Lead sponsor: Vifor Pharma; Industry
Eligibility: 20 Years to 50 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Anaheim, California

Conditions: Pharmacokinetics of Isavuconazole, Pharmacokinetics of Atorvastatin, Healthy Volunteers
Interventions: Isavuconazole, atorvastatin; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Rotator Cuff Tear Arthropathy
Interventions: Ibuprofen, Placebo; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Heroin Dependence
Interventions: Intranasal challenge drug; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 21 Years to 45 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Intracerebral Hemorrhage, Stroke, Hypertension
Interventions: Blood pressure management policies; Other
Lead sponsor: The George Institute; Other
Eligibility: 18 Years and older
Enrollment: 2,839 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Healthy Participants
Interventions: AZD6234, Ethinyl estradiol/Levonorgestrel (EE/LEVO), Acetaminophen (APAP), AZD9550; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 35 Years to 75 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Glendale, California • Brooklyn, Maryland

Conditions: Obesity, Tuberculosis
Interventions: Ethambutol; Drug
Lead sponsor: Texas Tech University Health Sciences Center; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: HIV Infections
Interventions: Ditiocarb sodium; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1996
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Breast Cancer
Interventions: high performance liquid chromatography, laboratory biomarker analysis, mass spectrometry, medical chart review; Other
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older · Female only
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2012
U.S. locations: 2
States / cities: Rochester, Minnesota • Omaha, Nebraska

Conditions: Pharmacokinetics, Safety, Food-drug Interaction
Interventions: 200 mg resveratrol as JOTROL, 500 mg resveratrol as JOTROL, 700 mg resveratrol as JOTROL, 500 mg resveratrol as JOTROL administered to assess influence of food; Drug
Lead sponsor: Jupiter Orphan Therapeutics Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Miami, Florida

Conditions: NASH - Nonalcoholic Steatohepatitis
Interventions: EDP-305, Oral Contraceptive; Drug
Lead sponsor: Enanta Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Madison, Wisconsin

Search by objective public record fields.

A Study to Determine the Bioavailability and Food Effect of a Single TAK-935 Dose in Healthy Participants

Pharmacokinetics, Efficacy and Safety of an Octreotide Implant in Patients With Carcinoid Syndrome

The Effect of Culinary Medicine to Enhance Protein Intake on Muscle Quality in Older Adults

The Multicenter Randomized HYpertension and VALUEs (HYVALUE) Trial

To Find Out Whether Valsartan With or Without Other Blood Pressure Medications Would Improve the Ability of the Heart to Fill and Empty, and the Ability of the Heart Muscle to Relax Adequately in People With High Blood Pressure.

A Drug-Drug Interaction Study of Itraconazole and Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-017)

Safety, Tolerability and Immunogenicity of a Plant-made Seasonal Quadrivalent VLP Influenza Vaccine in Adults

Quantifying the Attentive Behaviors of Older Adults During Over-the-counter Drug Selection

Study Evaluating the Effects of DVS SR and Paroxetine on the Pharmacokinetics of Desipramine in Healthy Subjects

A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in the United States

Effect of Alcohol and Drugs of Abuse on Immune Function in Critically Ill Patients With Respiratory Failure

MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations

Effects of MAC Preventive Therapy on Disease-Causing Bacteria in HIV-Infected Patients: A Substudy of CPCRA 048

A Drug-Drug Interaction Study of Furosemide and PA21

Drug Interaction Study of Multiple Doses of Isavuconazole and Single Dose of Atorvastatin

Effect of Ibuprofen on Postoperative Opiate Medication Use and Shoulder Functional Outcomes

Reinforcing Effects of Intranasal (IN) Buprenorphine Versus Buprenorphine/Naloxone

The Second Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial

A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesity

Effect of Weight and/or Obesity on Ethambutol Drug Concentrations

An Assessment of the In Vivo Biological Effects of Diethyldithiocarbamate (DTC) in HIV-Infected Patients

Effect of Tamoxifen or an Aromatase Inhibitor on Estrogen Metabolism in Women Treated for Newly Diagnosed Breast Cancer

JOTROL PK, Safety, and Food Effect Assessment

A Drug-drug Interaction Study to Investigate the Effect of Coadministration of EDP-305 on the PK of a Combined Oral Contraceptive in Healthy Female Subjects